Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

J. Scott Sawyer, Douglas W. Beight, Karen S. Britt, Bryan D. Anderson, Robert M. Campbell, Theodore Goodson, David K. Herron, Hong Yu Li, William T. McMillen, Nicholas Mort, Stephen Parsons, Edward C R Smith, Jill R. Wagner, Lei Yan, Faming Zhang, Jonathan M. Yingling

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-β type I receptor kinase domain (TβR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TβR-I receptor kinase domain.

Original languageEnglish (US)
Pages (from-to)3581-3584
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume14
Issue number13
DOIs
StatePublished - Jul 5 2004
Externally publishedYes

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Phosphotransferases
p38 Mitogen-Activated Protein Kinases
X ray analysis
Crystallization
Assays
X-Rays
Enzymes
pyrazole

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. / Sawyer, J. Scott; Beight, Douglas W.; Britt, Karen S.; Anderson, Bryan D.; Campbell, Robert M.; Goodson, Theodore; Herron, David K.; Li, Hong Yu; McMillen, William T.; Mort, Nicholas; Parsons, Stephen; Smith, Edward C R; Wagner, Jill R.; Yan, Lei; Zhang, Faming; Yingling, Jonathan M.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 14, No. 13, 05.07.2004, p. 3581-3584.

Research output: Contribution to journalArticle

Sawyer, JS, Beight, DW, Britt, KS, Anderson, BD, Campbell, RM, Goodson, T, Herron, DK, Li, HY, McMillen, WT, Mort, N, Parsons, S, Smith, ECR, Wagner, JR, Yan, L, Zhang, F & Yingling, JM 2004, 'Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain', Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 13, pp. 3581-3584. https://doi.org/10.1016/j.bmcl.2004.04.007
Sawyer, J. Scott ; Beight, Douglas W. ; Britt, Karen S. ; Anderson, Bryan D. ; Campbell, Robert M. ; Goodson, Theodore ; Herron, David K. ; Li, Hong Yu ; McMillen, William T. ; Mort, Nicholas ; Parsons, Stephen ; Smith, Edward C R ; Wagner, Jill R. ; Yan, Lei ; Zhang, Faming ; Yingling, Jonathan M. / Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. In: Bioorganic and Medicinal Chemistry Letters. 2004 ; Vol. 14, No. 13. pp. 3581-3584.
@article{1ab1b65ceab24de785245c9a24005074,
title = "Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain",
abstract = "We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-β type I receptor kinase domain (TβR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TβR-I receptor kinase domain.",
author = "Sawyer, {J. Scott} and Beight, {Douglas W.} and Britt, {Karen S.} and Anderson, {Bryan D.} and Campbell, {Robert M.} and Theodore Goodson and Herron, {David K.} and Li, {Hong Yu} and McMillen, {William T.} and Nicholas Mort and Stephen Parsons and Smith, {Edward C R} and Wagner, {Jill R.} and Lei Yan and Faming Zhang and Yingling, {Jonathan M.}",
year = "2004",
month = "7",
day = "5",
doi = "10.1016/j.bmcl.2004.04.007",
language = "English (US)",
volume = "14",
pages = "3581--3584",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "13",

}

TY - JOUR

T1 - Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

AU - Sawyer, J. Scott

AU - Beight, Douglas W.

AU - Britt, Karen S.

AU - Anderson, Bryan D.

AU - Campbell, Robert M.

AU - Goodson, Theodore

AU - Herron, David K.

AU - Li, Hong Yu

AU - McMillen, William T.

AU - Mort, Nicholas

AU - Parsons, Stephen

AU - Smith, Edward C R

AU - Wagner, Jill R.

AU - Yan, Lei

AU - Zhang, Faming

AU - Yingling, Jonathan M.

PY - 2004/7/5

Y1 - 2004/7/5

N2 - We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-β type I receptor kinase domain (TβR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TβR-I receptor kinase domain.

AB - We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-β type I receptor kinase domain (TβR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TβR-I receptor kinase domain.

UR - http://www.scopus.com/inward/record.url?scp=2942589081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942589081&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2004.04.007

DO - 10.1016/j.bmcl.2004.04.007

M3 - Article

C2 - 15177479

AN - SCOPUS:2942589081

VL - 14

SP - 3581

EP - 3584

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 13

ER -